A prospective trial with ketoconazole and octreotide combination therapy for treatment of Cushing*s disease.

Phase 2

Completed

• Conditions: Cushing's disease; pituitary ACTH hypersecretion; 10021112

• Registration Number: NL-OMON36055
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Biochemically confirmed ACTH dependent Cushing's syndrome originating from a pituitary adenoma (either de novo, recurrent or residual)

Exclusion Criteria

Impaired liver function
Renal insufficiency
Symptomatic cholelithiasis
History of pituitary irradiation
Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Urinary free cortisol<br /><br>Midnight salivary cortisol</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Cortisol diurnal rhythm measured in saliva and serum<br /><br>Quality of life<br /><br>Parameters of coagulation and fibrinolysis<br /><br>Bone density and serummarkers for bone turnover</p><br>